{"id":36565,"date":"2025-07-03T15:12:27","date_gmt":"2025-07-03T07:12:27","guid":{"rendered":"https:\/\/flcube.com\/?p=36565"},"modified":"2025-07-03T15:12:27","modified_gmt":"2025-07-03T07:12:27","slug":"abbvies-venclexta-approved-by-chinas-nmpa-for-cll-sll-patients-with-17p-deletion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36565","title":{"rendered":"AbbVie’s Venclexta Approved by China’s NMPA for CLL\/SLL Patients with 17p Deletion"},"content":{"rendered":"\n

US-based major AbbVie Inc., (NYSE: ABBV<\/a>) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.<\/p>\n\n\n\n

Global Commercialization<\/strong>
Venclexta is jointly commercialized by AbbVie and Genentech (a member of the Roche Group) in the US. Outside the US, AbbVie is solely responsible for commercialization. The drug has been approved in over 80 countries\/regions worldwide, including the US. It is the subject of clinical studies in multiple hematological malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s…<\/p>\n","protected":false},"author":1,"featured_media":36566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[234,16,853,940,15,163,939],"class_list":["post-36565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-cancer","tag-nyse-abbv","tag-otcmkts-rhhby","tag-product-approvals","tag-roche","tag-swx-rop"],"yoast_head":"\nAbbVie's Venclexta Approved by China's NMPA for CLL\/SLL Patients with 17p Deletion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36565\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie's Venclexta Approved by China's NMPA for CLL\/SLL Patients with 17p Deletion\" \/>\n<meta property=\"og:description\" content=\"US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36565\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-03T07:12:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie’s Venclexta Approved by China’s NMPA for CLL\\\/SLL Patients with 17p Deletion\",\"datePublished\":\"2025-07-03T07:12:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565\"},\"wordCount\":155,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0305.webp\",\"keywords\":[\"AbbVie\",\"Cancer\",\"NYSE: ABBV\",\"OTCMKTS: RHHBY\",\"Product approvals\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36565#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36565\",\"name\":\"AbbVie's Venclexta Approved by China's NMPA for CLL\\\/SLL Patients with 17p Deletion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0305.webp\",\"datePublished\":\"2025-07-03T07:12:27+00:00\",\"description\":\"US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\\\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36565\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0305.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie's Venclexta Approved by China's NMPA for CLL\\\/SLL Patients with 17p Deletion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36565#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie’s Venclexta Approved by China’s NMPA for CLL\\\/SLL Patients with 17p Deletion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie's Venclexta Approved by China's NMPA for CLL\/SLL Patients with 17p Deletion - Insight, China's Pharmaceutical Industry","description":"US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36565","og_locale":"en_US","og_type":"article","og_title":"AbbVie's Venclexta Approved by China's NMPA for CLL\/SLL Patients with 17p Deletion","og_description":"US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.","og_url":"https:\/\/flcube.com\/?p=36565","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-03T07:12:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36565#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36565"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie’s Venclexta Approved by China’s NMPA for CLL\/SLL Patients with 17p Deletion","datePublished":"2025-07-03T07:12:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36565"},"wordCount":155,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36565#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp","keywords":["AbbVie","Cancer","NYSE: ABBV","OTCMKTS: RHHBY","Product approvals","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36565#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36565","url":"https:\/\/flcube.com\/?p=36565","name":"AbbVie's Venclexta Approved by China's NMPA for CLL\/SLL Patients with 17p Deletion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36565#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36565#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp","datePublished":"2025-07-03T07:12:27+00:00","description":"US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Venclexta (venetoclax), a first-in-class BCL-2 inhibitor co-developed by Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). The drug is approved for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) harboring the 17p deletion mutation, who have received at least one prior therapy. This approval makes Venclexta the first of its kind globally as a targeted CLL treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36565#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36565"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36565#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp","width":1080,"height":608,"caption":"AbbVie's Venclexta Approved by China's NMPA for CLL\/SLL Patients with 17p Deletion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36565#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie’s Venclexta Approved by China’s NMPA for CLL\/SLL Patients with 17p Deletion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36565"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36565\/revisions"}],"predecessor-version":[{"id":36567,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36565\/revisions\/36567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36566"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}